TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Mylan said to raise Meda takeover offer to $6.7B

Daily Photo Galleries

By Staff and Wire Reports
Friday, April 25, 2014, 2:39 p.m.
 

Mylan Inc., the biggest domestic maker of generic medicines, raised its offer for Swedish drugmaker Meda AB to about $6.7 billion, people with knowledge of the matter said.

The all-stock offer was sent this week, said the people, who asked not to be identified discussing confidential information.

A previous Mylan bid was rejected by Meda, the Swedish company said on April 4, without saying why or disclosing the offer's amount.

Meda would help Cecil-based Mylan expand in generic and branded respiratory and dermatology drugs, and strengthen its position in emerging markets and Europe.

Among Meda's products is the allergy drug Dymista. A majority of Mylan's products are generic versions of branded pharmaceuticals. But it makes EpiPen, a branded drug used to treat severe allergic reactions.

Generic drug manufacturers have been consolidating and buying up new assets as a way to broaden their revenue to include more profitable brand-name drugs and injectable medicines that face less competition.

Mylan has said it is looking to make a “substantial” acquisition this year. The company in December completed a $1.75 billion acquisition of Agila, an Indian maker of injectable medications that doubled the size of Mylan's injectables business.

Nina Devlin, a spokeswoman for Mylan, and Paula Treutiger, a Meda spokeswoman, declined to comment.

Meda's shares were halted in Stockholm trading on Friday. Mylan gained more than 3 percent to close at $52.10.

Actavis Plc, an Irish drugmaker with operations in New Jersey, in February agreed to buy Forest Laboratories Inc. for $25 billion. Valeant Pharmaceuticals International Inc. has been gobbling up drug and health products companies as it seeks to grow into one of the world's five biggest drug manufacturers.

Valeant this week teamed with Bill Ackman, a billionaire hedge fund manager, in a $45.7 billion bid to buy Allergan Inc., the maker of the Botox cosmetic treatment.

Bloomberg News and Trib Total Media staff writer Alex Nixon contributed to this report. Nixon can be reached at 412-320-7928 or anixon@tribweb.com.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Home price gains slow for 6th-straight month
  2. Tech giants lead rush for profits in foreign countries
  3. Hotels, restaurants lead job additions in Pittsburgh region
  4. GNC revenue, sales drop, but vitamin retailer says plan in place
  5. Fed to keep cards close to the vest
  6. Jimmy Dean moves beyond breakfast
  7. China investigates Microsoft in monopoly case
  8. U.S. Steel’s 2Q loss beats analysts’ estimates
  9. Market in neutral, awaiting economic news
  10. Consumer confidence jumps to 90.9 in July
  11. Hiring in shale industry shifts to engineering, construction workers
Subscribe today! Click here for our subscription offers.